Accuray Inc. said Wednesday it received Food and Drug Administration marketing clearance for a component of its CyberKnife radiation therapy device.
The company said the component is used in the treatment of lung cancer, one of the conditions CyberKnife VSI systems are approved to treat.
Shares of Accuray climbed 66 cents, or 11 percent, to $6.91 in morning trading. The stock has traded between $5.36 and $7.75 over the last year.
The CyberKnife system is designed to treat cancer by beaming large, precise doses of radiation into tumors while avoiding healthy tissue. It is designed to kill the tumors without surgery, making some treatments outpatient procedures and allowing the treatment of inoperable tumors. The device has been on the U.S. market since 1999, and it is used to treat cancers in the lungs, spine, prostate, liver, and pancreas.
Accuray said treatment of lung tumors is particularly difficult because the lungs move as the patient breathes, and because the lungs are near other important organs.